PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study
- 1 January 2017
- journal article
- abstracts
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 12 (1), S10-S11
- https://doi.org/10.1016/j.jtho.2016.11.012